Antithrombotic Therapy after Ablation for Atrial Fibrillation
May 7, 2026DOI: 10.1056/nejmc2602513CorrespondenceNEJM
To the Editor: In the recent OCEAN (Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation) trial involving patients who had undergone successful catheter ablation for atrial fibrillation, Verma et al. (Jan. 22 issue) report that the incidence of the primary trial outcome (a composite of stroke, systemic embolism, or new covert embolic stroke) was not significantly lower among those treated with reduced-dose rivaroxaban (15 mg per day) than among those treated with aspirin. Generalizing the results of this trial to the patient population with atrial fibrillation may be challenging because the mean CHA2DS2-VASc score (scores range from . . .